FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1602607558> ?p ?o ?g. }

• W1602607558 abstract "The FAVOURED study is an international multicentre, double-blind, placebo-controlled trial which commenced recruitment in 2008 and examines whether omega-3 polyunsaturated fatty acids (omega-3 PUFAs) either alone or in combination with aspirin will effectively reduce primary access failure of de novo arteriovenous fistulae (AVF) in patients with stage 4 and 5 chronic kidney disease. Publication of new evidence derived from additional studies of clopidogrel and a high screen failure rate due to prevalent aspirin usage prompted an updated trial design.The original trial protocol published in 2009 has undergone two major amendments, which were implemented in 2011. Firstly, the primary outcome 'early thrombosis' at 3 months following AVF creation was broadened to a more clinically relevant outcome of 'AVF access failure'; a composite of thrombosis, AVF abandonment and cannulation failure at 12 months. Secondly, participants unable to cease using aspirin were allowed to be enrolled and randomised to omega-3 PUFAs or placebo. The revised primary aim of the FAVOURED study is to test the hypothesis that omega-3 PUFAs will reduce rates of AVF access failure within 12 months following AVF surgery. The secondary aims are to examine the effect of omega-3 PUFAs and aspirin on the individual components of the primary end-point, to examine the safety of study interventions and assess central venous catheter requirement as a result of access failure.This multicentre international clinical trial was amended to address the clinically relevant question of whether the usability of de novo AVF at 12 months can be improved by the early use of omega-3 PUFAs and to a lesser extent aspirin. This study protocol amendment was made in response to a large trial demonstrating that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. Secondly, including patients taking aspirin will enroll a more representative cohort of haemodialysis patients, who are significantly older with a higher prevalence of cardiovascular disease and diabetes which may increase event rates and the power of the study.Australia & New Zealand Clinical Trial Register (ACTRN12607000569404)." @default.
• W1602607558 created "2016-06-24" @default.
• W1602607558 creator A5001097962 @default.
• W1602607558 creator A5012365523 @default.
• W1602607558 creator A5018662602 @default.
• W1602607558 creator A5019279914 @default.
• W1602607558 creator A5024768204 @default.
• W1602607558 creator A5045012584 @default.
• W1602607558 creator A5046699193 @default.
• W1602607558 creator A5062613865 @default.
• W1602607558 creator A5073030703 @default.
• W1602607558 creator A5075474387 @default.
• W1602607558 creator A5087336965 @default.
• W1602607558 creator A5089174684 @default.
• W1602607558 creator A5090037493 @default.
• W1602607558 date "2015-06-27" @default.
• W1602607558 modified "2023-10-18" @default.
• W1602607558 title "The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications" @default.
• W1602607558 cites W1502557493 @default.
• W1602607558 cites W1966330492 @default.
• W1602607558 cites W1979187236 @default.
• W1602607558 cites W1984450372 @default.
• W1602607558 cites W1986862277 @default.
• W1602607558 cites W2026385971 @default.
• W1602607558 cites W2055389089 @default.
• W1602607558 cites W2073772081 @default.
• W1602607558 cites W2086227507 @default.
• W1602607558 cites W2094129893 @default.
• W1602607558 cites W2100928282 @default.
• W1602607558 cites W2104328185 @default.
• W1602607558 cites W2108659066 @default.
• W1602607558 cites W2119345183 @default.
• W1602607558 cites W2129663436 @default.
• W1602607558 cites W2135559852 @default.
• W1602607558 cites W2138678834 @default.
• W1602607558 cites W2150842759 @default.
• W1602607558 cites W2169089638 @default.
• W1602607558 cites W2254934747 @default.
• W1602607558 cites W2414963831 @default.
• W1602607558 doi "https://doi.org/10.1186/s12882-015-0089-2" @default.
• W1602607558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4482267" @default.
• W1602607558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26116581" @default.
• W1602607558 hasPublicationYear "2015" @default.
• W1602607558 type Work @default.
• W1602607558 sameAs 1602607558 @default.
• W1602607558 citedByCount "20" @default.
• W1602607558 countsByYear W16026075582015 @default.
• W1602607558 countsByYear W16026075582016 @default.
• W1602607558 countsByYear W16026075582017 @default.
• W1602607558 countsByYear W16026075582018 @default.
• W1602607558 countsByYear W16026075582019 @default.
• W1602607558 countsByYear W16026075582020 @default.
• W1602607558 countsByYear W16026075582021 @default.
• W1602607558 countsByYear W16026075582022 @default.
• W1602607558 crossrefType "journal-article" @default.
• W1602607558 hasAuthorship W1602607558A5001097962 @default.
• W1602607558 hasAuthorship W1602607558A5012365523 @default.
• W1602607558 hasAuthorship W1602607558A5018662602 @default.
• W1602607558 hasAuthorship W1602607558A5019279914 @default.
• W1602607558 hasAuthorship W1602607558A5024768204 @default.
• W1602607558 hasAuthorship W1602607558A5045012584 @default.
• W1602607558 hasAuthorship W1602607558A5046699193 @default.
• W1602607558 hasAuthorship W1602607558A5062613865 @default.
• W1602607558 hasAuthorship W1602607558A5073030703 @default.
• W1602607558 hasAuthorship W1602607558A5075474387 @default.
• W1602607558 hasAuthorship W1602607558A5087336965 @default.
• W1602607558 hasAuthorship W1602607558A5089174684 @default.
• W1602607558 hasAuthorship W1602607558A5090037493 @default.
• W1602607558 hasBestOaLocation W16026075581 @default.
• W1602607558 hasConcept C126322002 @default.
• W1602607558 hasConcept C142724271 @default.
• W1602607558 hasConcept C168563851 @default.
• W1602607558 hasConcept C203092338 @default.
• W1602607558 hasConcept C204787440 @default.
• W1602607558 hasConcept C27081682 @default.
• W1602607558 hasConcept C2777628954 @default.
• W1602607558 hasConcept C2778653478 @default.
• W1602607558 hasConcept C2780868729 @default.
• W1602607558 hasConcept C535046627 @default.
• W1602607558 hasConcept C71924100 @default.
• W1602607558 hasConceptScore W1602607558C126322002 @default.
• W1602607558 hasConceptScore W1602607558C142724271 @default.
• W1602607558 hasConceptScore W1602607558C168563851 @default.
• W1602607558 hasConceptScore W1602607558C203092338 @default.
• W1602607558 hasConceptScore W1602607558C204787440 @default.
• W1602607558 hasConceptScore W1602607558C27081682 @default.
• W1602607558 hasConceptScore W1602607558C2777628954 @default.
• W1602607558 hasConceptScore W1602607558C2778653478 @default.
• W1602607558 hasConceptScore W1602607558C2780868729 @default.
• W1602607558 hasConceptScore W1602607558C535046627 @default.
• W1602607558 hasConceptScore W1602607558C71924100 @default.
• W1602607558 hasIssue "1" @default.
• W1602607558 hasLocation W16026075581 @default.
• W1602607558 hasLocation W16026075582 @default.
• W1602607558 hasLocation W16026075583 @default.
• W1602607558 hasLocation W16026075584 @default.
• W1602607558 hasLocation W16026075585 @default.
• W1602607558 hasOpenAccess W1602607558 @default.
• W1602607558 hasPrimaryLocation W16026075581 @default.
• W1602607558 hasRelatedWork W2017773083 @default.

• next